Demyelinating diseases

Section edited by Francesco Patti and Tjalf Ziemssen

This section covers all types of demyelinating diseases. Topics of interest include, but are not limited to, multiple sclerosis, neuroimmunology, systemic lupus, vasculitis, lymphoma, and myelitis.

Previous Page Page 1 of 10 Next Page
  1. Research article

    Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial

    Subcutaneous peginterferon beta-1a has previously been shown to reduce the number of T2-hyperintense and gadolinium-enhancing (Gd+) lesions over 2 years in patients with relapsing-remitting multiple sclerosis ...

    Douglas L. Arnold, Peter A. Calabresi, Bernd C. Kieseier, Shifang Liu, Xiaojun You, Damian Fiore and Serena Hung

    BMC Neurology 2017 17:29

    Published on: 10 February 2017

  2. Research article

    Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study

    The low level of disease activity and manageable safety profile seen with fingolimod versus placebo in a 6-month, phase 2, randomized controlled trial in Japanese patients with relapsing multiple sclerosis (MS...

    Takahiko Saida, Yasuto Itoyama, Seiji Kikuchi, Qi Hao, Takayoshi Kurosawa, Kengo Ueda, Lixin Zhang Auberson, Isao Tsumiyama, Kazuo Nagato and Jun-ichi Kira

    BMC Neurology 2017 17:17

    Published on: 28 January 2017

  3. Case report

    LETM presented with causalgia and ensued by sudden death

    Longitudinally Extensive Transverse Myelitis LETM is a specific pattern of myelitis wherein at least three continuous vertebral segments are involved. Characteristically, it is a defining feature of neuromyeli...

    Rana Alnasser Alsukhni, Yasmin Aboras, Ziena Jriekh, Mahmoud Almalla and Ahmad Sheikh El-Kahwateya

    BMC Neurology 2017 17:13

    Published on: 21 January 2017

  4. Research article

    Electrocardiographic assessments and cardiac events after fingolimod first dose – a comprehensive monitoring study

    First dose observation for cardiac effects is required for fingolimod, but recommendations on the extent vary. This study aims to assess cardiac safety of fingolimod first dose. Individual bradyarrhythmic epis...

    Volker Limmroth, Tjalf Ziemssen, Michael Lang, Stephan Richter, Bert Wagner, Judith Haas, Stephan Schmidt, Kathrin Gerbershagen, Christoph Lassek, Luisa Klotz, Olaf Hoffmann, Christian Albert, Katrin Schuh, Monika Baier-Ebert, Guillaume Wendt, Heinke Schieb…

    BMC Neurology 2017 17:11

    Published on: 18 January 2017

  5. Research article

    Subjective and objective assessment of physical activity in multiple sclerosis and their relation to health-related quality of life

    Physical activity (PA) is frequently restricted in people with multiple sclerosis (PwMS) and aiming to enhance PA is considered beneficial in this population. We here aimed to explore two standard methods (sub...

    Theresa Krüger, Janina R. Behrens, Anuschka Grobelny, Karen Otte, Sebastian Mansow-Model, Bastian Kayser, Judith Bellmann-Strobl, Alexander U. Brandt, Friedemann Paul and Tanja Schmitz-Hübsch

    BMC Neurology 2017 17:10

    Published on: 13 January 2017

  6. Research article

    Screening for onconeural antibodies in neuromyelitis optica spectrum disorders

    Some so-called “non-classical” paraneoplastic neurological syndromes (PNS), namely optic neuritis and myelitis, clinically overlap with neuromyelitis optica spectrum disorders (NMOSD), and conversely, in cance...

    Benjamin Berger, Tilman Hottenrott, Sebastian Rauer and Oliver Stich

    BMC Neurology 2017 17:5

    Published on: 10 January 2017

  7. Case report

    Anti-N-methyl-D-aspartate receptor(NMDAR) antibody encephalitis presents in atypical types and coexists with neuromyelitis optica spectrum disorder or neurosyphilis

    Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a clinically heterogeneous disorder characterized by epileptic seizures, psychosis, dyskinesia, consciousness impairments, and autonomic instability. ...

    Kaiyu Qin, Wenqing Wu, Yuming Huang, Dongmei Xu, Lei Zhang, Bowen Zheng, Meijuan Jiang, Cheng Kou, Junhua Gao, Wurong Li, Jinglin Zhang, Sumei Wang, Yanfei Luan, Chaoling Yan, Dan Xu and Xinmei Zheng

    BMC Neurology 2017 17:1

    Published on: 5 January 2017

  8. Research article

    Bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10 years of disease - a case control study

    Although disability is considered the main cause of low bone mineral density (BMD) in multiple sclerosis (MS), other factors related to the disease process or treatment could also be involved. The aim of this ...

    Cecilia Smith Simonsen, Elisabeth Gulowsen Celius, Cathrine Brunborg, Chantal Tallaksen, Erik Fink Eriksen, Trygve Holmøy and Stine Marit Moen

    BMC Neurology 2016 16:252

    Published on: 5 December 2016

  9. Research article

    A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis

    Multiple sclerosis (MS) is a chronic autoimmune disease characterized by inflammatory and neurodegenerative processes leading to irreversible neurological impairment. Brain atrophy occurs early in the course o...

    Raed Alroughani, Dirk Deleu, Khalid El Salem, Jasem Al-Hashel, K. John Alexander, Mohamed Assem Abdelrazek, Adel Aljishi, Jaber Alkhaboori, Faisal Al Azri, Nahida Al Zadjali, Majed Hbahbih, Tag Eldin Sokrab, Mohamed Said and Àlex Rovira

    BMC Neurology 2016 16:240

    Published on: 24 November 2016

  10. Research article

    Lifestyle, medication and socio-demographic determinants of mental and physical health-related quality of life in people with multiple sclerosis

    Health-related quality of life (QOL) is a key outcome for people with multiple sclerosis (MS). While modifiable lifestyle factors, like smoking, physical activity and vitamin D, have strong associations with d...

    George A Jelinek, Alysha M De Livera, Claudia H Marck, Chelsea R Brown, Sandra L Neate, Keryn L Taylor and Tracey J Weiland

    BMC Neurology 2016 16:235

    Published on: 22 November 2016

  11. Research article

    Sexual function in multiple sclerosis and associations with demographic, disease and lifestyle characteristics: an international cross-sectional study

    Sexual dysfunction (SD) is very common in people with multiple sclerosis (PwMS) and contributes a significant burden of disease, particularly for young people. SD has direct neurological contributions from dep...

    Claudia H. Marck, Pia L. Jelinek, Tracey J. Weiland, Jane S. Hocking, Alysha M. De Livera, Keryn L. Taylor, Sandra L. Neate, Naresh G. Pereira and George A. Jelinek

    BMC Neurology 2016 16:210

    Published on: 4 November 2016

  12. Research article

    The role of anti-aquaporin 4 antibody in the conversion of acute brainstem syndrome to neuromyelitis optica

    Acute brainstem syndrome (ABS) may herald multiple sclerosis (MS), neuromyelitis optica (NMO), or occur as an isolated syndrome. The aquaporin 4 (AQP4)-specific serum autoantibody, NMO-IgG, is a biomarker for ...

    Chen Cheng, Ying Jiang, Xiaodong Lu, Fu Gu, Zhuang Kang, Yongqiang Dai, Zhengqi Lu and Xueqiang Hu

    BMC Neurology 2016 16:203

    Published on: 21 October 2016

  13. Research article

    The relevance of cortical lesions in patients with multiple sclerosis

    Recent studies suggest that cortical lesions in multiple sclerosis (MS) substantially contribute to clinical disease severity. The present study aimed at investigating clinical, neuroanatomical, and cognitive ...

    Olivia Geisseler, Tobias Pflugshaupt, Ladina Bezzola, Katja Reuter, David Weller, Bernhard Schuknecht, Peter Brugger and Michael Linnebank

    BMC Neurology 2016 16:204

    Published on: 21 October 2016

  14. Case report

    Severe inflammatory disease activity 14 months after cessation of Natalizumab in a patient with Leber’s optic neuropathy and multiple sclerosis – a case report

    Leber’s hereditary optic neuropathy (LHON) co-occuring with multiple sclerosis-like disease (LHON-MS) is suggested to be a separate disease entity denoted Harding’s disease. Little is known about the response ...

    Trygve Holmøy, Antonie G. Beiske, Svetozar Zarnovicky, Aija Zuleron Myro, Egil Røsjø and Emilia Kerty

    BMC Neurology 2016 16:197

    Published on: 18 October 2016

  15. Research article

    Persistency, medication prescribing patterns, and medical resource use associated with multiple sclerosis patients receiving oral disease-modifying therapies: a retrospective medical record review

    In the US, the approved multiple sclerosis (MS) oral disease-modifying therapies (ODMTs) are fingolimod (FTY), teriflunomide (TFN), and dimethyl fumarate (DMF). FTY and TFN are recommended with once-daily dose...

    Tara Nazareth, Howard S. Friedman, Prakash Navaratnam, Denise A. Herriott, John J. Ko, Peri Barr and Rahul Sasane

    BMC Neurology 2016 16:187

    Published on: 29 September 2016

  16. Research article

    MRI utility in the detection of disease activity in clinically stable patients with multiple sclerosis: a retrospective analysis of a community based cohort

    Since the application of MRI scanning to the diagnosis and treatment of multiple sclerosis, it has been recognized that only a small fraction of lesions seen on MRI scans produce recognizable symptoms or neuro...

    Stanley Cohan, Chiayi Chen, Elizabeth Baraban, Tamela Stuchiner and Lois Grote

    BMC Neurology 2016 16:184

    Published on: 22 September 2016

  17. Research article

    Comparative evaluation of patients’ and physicians’ satisfaction with interferon beta-1b therapy

    Due to the preventive nature of disease-modifying therapies for multiple sclerosis, treatment success particularly depends on adherence to therapeutic regimens and patients’ perception of treatment efficacy. T...

    Uwe Klaus Zettl, Ulrike Bauer-Steinhusen, Thomas Glaser, Klaus Hechenbichler and Michael Hecker

    BMC Neurology 2016 16:181

    Published on: 21 September 2016

Previous Page Page 1 of 10 Next Page

Can't find what you are looking for?

Articles for this section are still being added to this new-look site. In the meantime you can still view this section on our old site.